Trade

with

EnteroMedics Inc
(NASDAQ: ETRM)
AdChoices
1.15
+0.01
+0.88%
After Hours :
-
-
-

Open

1.14

Previous Close

1.14

Volume (Avg)

490.34k (636.56k)

Day's Range

1.14-1.24

52Wk Range

0.9900-2.66

Market Cap.

78.53M

Dividend Rate ( Yield )

-

Beta

2.16

Shares Outstanding

68.89M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Medical Devices
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 0

    • Net Income

    • -25.78M

    • Market Cap.

    • 78.53M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.16

    • Forward P/E

    • -2.59

    • Price/Sales

    • -

    • Price/Book Value

    • 5.35

    • Price/Cash flow

    • -3.44

      • EBITDA

      • -24.67M

      • Return on Capital %

      • -105.71

      • Return on Equity %

      • -190.15

      • Return on Assets %

      • -105.71

      • Book Value/Share

      • 0.21

      • Shares Outstanding

      • 68.89M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 4.33

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -0.44

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 2.66

          • Net Income

            YTD/YTD (last year)

          • -

          • -22.64

          • Net Income

            Q/Q (last year)

          • -

          • -29.83

          • Sales (Revenue)

            5-Year Annual Average

          • 0.00

          • 4.60

          • Net Income

            5-Year Annual Average

          • -

          • -1.34

          • Dividends

            5-Year Annual Average

          • -

          • -0.25

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 64.08

            • Pre-Tax Margin

            • -

            • 15.19

            • Net Profit Margin

            • -

            • 13.09

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 65.03

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 17.99

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 191.75B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.06

              • 0.34

              • Current Ratio

              • 2.60

              • 2.55

              • Quick Ratio

              • 2.46

              • 1.83

              • Interest Coverage

              • -35.71

              • 11.70

              • Leverage Ratio

              • 1.66

              • 1.86

              • Book Value/Share

              • 0.21

              • 11.69

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -2.38

                • 34.01

                • P/E Ratio 5-Year High

                • -19.98

                • 224.03

                • P/E Ratio 5-Year Low

                • -1.87

                • 60.23

                • Price/Sales Ratio

                • -

                • 3.17

                • Price/Book Value

                • 4.84

                • 3.20

                • Price/Cash Flow Ratio

                • -3.44

                • 18.42

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -190.15

                    (-184.00)

                  • 12.33

                    (18.16)

                  • Return on Assets %

                    (5-Year Average)

                  • -105.71

                    (-91.60)

                  • 6.62

                    (8.69)

                  • Return on Capital %

                    (5-Year Average)

                  • -124.89

                    (-115.90)

                  • 8.49

                    (11.48)

                  • Income/Employee

                  • -

                  • 34.11k

                  • Inventory Turnover

                  • -

                  • 2.77

                  • Asset Turnover

                  • -

                  • 0.51

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -24.73M
                  Operating Margin
                  -
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -3.44
                  Ownership

                  Institutional Ownership

                  29.84%

                  Top 10 Institutions

                  24.43%

                  Mutual Fund Ownership

                  11.99%

                  Float

                  69.39%

                  5% / Insider Ownership

                  0.19%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • T. Rowe Price New Horizons Fund

                  •  

                    1,702,100

                  • -0.11

                  • 2.47

                  • T. Rowe Price Health Sciences Fund

                  •  

                    1,644,700

                  • -0.32

                  • 2.39

                  • Vanguard Total Stock Mkt Idx

                  •  

                    869,754

                  • 0.00

                  • 1.26

                  • Wells Fargo Advantage Sm/Mid Cap Val

                  •  

                    780,600

                  • -3.82

                  • 1.13

                  • Alger Health Sciences Portfolio

                  •  

                    651,000

                  • 0.00

                  • 0.95

                  • Vanguard Extended Market Index Fund

                  •  

                    491,934

                  • 10.32

                  • 0.71

                  • Royce Micro Cap Series Fund

                  •  

                    344,300

                  • -39.85

                  • 0.50

                  • Royce Capital Fund Micro-Cap Portfolio

                  •  

                    275,300

                  • -39.47

                  • 0.40

                  • Finen Inversiones SICAV

                  •  

                    250,186

                  • 25.15

                  • 0.37

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    152,453

                  • 0.00

                  • 0.22

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Bay City Capital LLC

                  •  

                    4,904,450

                  • 0.00%

                  • 7.37

                  • T. Rowe Price Associates, Inc.

                  •  

                    4,054,370

                  • -0.13%

                  • 5.89

                  • Wells Capital Management Inc.

                  •  

                    1,773,630

                  • -37.10%

                  • 2.57

                  • Vanguard Group, Inc.

                  •  

                    1,329,954

                  • +7.81%

                  • 1.93

                  • Mpm Asset Management, LLC

                  •  

                    1,113,168

                  • 0.00%

                  • 1.62

                  • Royce & Associates, LLC

                  •  

                    1,060,000

                  • -17.51%

                  • 1.54

                  • Rock Springs Capital Management LP

                  •  

                    850,000

                  • +30.77%

                  • 1.23

                  • Iguana Healthcare Management, LLC

                  •  

                    600,000

                  • -47.83%

                  • 0.87

                  • Bailard, Inc.

                  •  

                    317,700

                  • 0.00%

                  • 0.46

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Medical Devices

                  Type

                  Distressed

                  Style

                  Small Core

                  EnteroMedics Inc was incorporated in Minnesota on December 19, 2002. The Company is a development stage medical device company with approvals to commercially launch its product in Australia, the European Economic Area and other count...moreries that recognize the European CE Mark. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. Its proprietary neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve using high frequency, low energy, electrical impulses. The Company has limited operating history and currently only has regulatory approval to sell its product in Australia, the European Economic Area and other countries that rec...moreognize the European CE Mark. Its initial product is the Maestro System, which uses VBLOC therapy to affect metabolic regulatory control, limits the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company competes in the market for obesity treatment with surgical obesity procedures and various devices used to implement neurostimulation and gastric stimulation systems. Its competitors include: Abbott Labs, Roche, GlaxoSmithKline and Arena Pharmaceuticals, Inc. The Company's trademarks include: VBLOC, ENTEROMEDICS, MAESTRO, MAESTRO SYSTEM ORCHESTRATING OBESITY SOLUTIONS, VBLOC POWER TO CHOOSE and VBLOC POWER TO CHOOSE AND DESIGN are the subject of either a trademark registration or application for registration in Australia, Brazil, China, the European Community, India, Kuwait, Mexico, Saudi Arabia, Switzerland and the United Arab Emirates. The Company uses third parties to manufacture its Maestro System to minimize its capital investment, help control costs and take advantage of the expertise these third parties have in the large-scale production of medical devices. Its Maestro System is regulated by the FDA as a medical device under the Federal Food, Drug, and Cosmetic Act or FFDCA and the regulations promulgated under the FFDCA. Pursuant to the FFDCA, the FDA regulates the research, design, testing, manufacture, safety, labeling, storage, record keeping, advertising, sales and distribution, post-market adverse event reporting, production and advertising and promotion of medical devices in the United States.lessless

                  Key People

                  Mark B. Knudson,PhD

                  CEO/Chairman of the Board/Director/President

                  Greg S. Lea

                  COO/CFO/Chief Accounting Officer/Senior VP

                  Dr. Katherine S. Tweden,PhD

                  Vice President, Divisional

                  Mr. Jon T. Tremmel

                  Director

                  Dr. Carl S. Goldfischer,M.D.

                  Director

                  • EnteroMedics Inc

                  • 2800 Patton Road

                  • St. Paul, MN 55113

                  • USA.Map

                  • Phone: +1 651 634-3003

                  • Fax: +1 651 634-3212

                  • enteromedics.com

                  Incorporated

                  2002

                  Employees

                  27

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: